Study of Combination of Metformin and Pregabalin on HbA1c and DASS21in Diabetic Patients Suffering from Anxiety

People diagnosed with DM are approximately 20%
more likely to suffer from anxiety than those without
diabetes. Metformin is the first line therapy for treating
T2DM, whereas pregabalin is the first line therapy for
treating diabetic neuropathy as well as generalized anx
iety disorder (GAD). The objective of this study was to
investigate the effect of combining pregabalin with met
formin in patients who suffer from anxiety and see to
what extent does it reduce anxiety symptoms as well as
their glycated hemoglobin level. Related data were col
lected from T2DM individuals that were undergoing
treatment with metformin alone and those with met
formin and pregabalin combination. A greater decre
ment in anxiety symptoms and HbA1c occurred in pa
tients taking the combination therapy. Besides pregaba
lin’s use to decrease neuropathy symptoms it can also
alleviate anxiety symptoms in diabetic patients bringing
about a better glycemic control in them.